With 0.73 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.8 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $94.98 whereas the lowest price it dropped to was $90.47. The 52-week range on BPMC shows that it touched its highest point at $101.00 and its lowest point at $43.89 during that stretch. It currently has a 1-year price target of $98.00. Beta for the stock currently stands at 0.66.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BPMC was up-trending over the past week, with a rise of 7.08%, but this was down by -1.89% over a month. Three-month performance surged to 14.03% while six-month performance rose 111.56%. The stock gained 89.72% in the past year, while it has gained 0.82% so far this year. A look at the trailing 12-month EPS for BPMC yields -8.37 with Next year EPS estimates of -2.82. For the next quarter, that number is -1.67. This implies an EPS growth rate of 33.13% for this year and 49.61% for next year.
Float and Shares Shorts:
At present, 61.15 million BPMC shares are outstanding with a float of 59.80 million shares on hand for trading. On 2024-04-15, short shares totaled 4.25 million, which was 692.99996 higher than short shares on 1710460800. In addition to Ms. Kathryn Haviland as the firm’s President, CEO & Director, Mr. Alexis A. Borisy A.M. serves as its Co-Founder & Director.
Institutional Ownership:
Through their ownership of 1.05218 of BPMC’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2023-12-31, BPMC reported revenue of $71957000.0 and operating income of -$105154000.0. The EBITDA in the recently reported quarter was -$121931000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BPMC since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
